The correlation of the related signaling pathways and prognosis in patients with advanced cholangiocarcinoma
10.3872/j.issn.1007-385x.2019.02.013
- VernacularTitle:晚期胆管细胞癌患者相关信号通路及其变异与预后的关系
- Author:
TAO Chenjie
1
;
YANG Guang
1
;
YUAN Zhengang
1
;
ZENG Tianmei
1
Author Information
1. Department of Oncology, Eastern Hepatobiliary Surgery Hospital，
- Publication Type:Journal Article
- Keywords:
cholangiocarcinoma;
the next generation sequencing technology;
total exons
- From:
Chinese Journal of Cancer Biotherapy
2019;26(2):220-224
- CountryChina
- Language:Chinese
-
Abstract:
Objective： ：To detect the gene mutation in cholangiocarcinoma patients using the next generation sequencing (NGS) technology, and to analyze its correlation to the prognosis of the patients. Methods: From June 2016 to June 2018, 40 patients diagnosed with cholangiocarcinoma received NGS examination to screen the possible mutations (single base mutation, structural variation, copy number variation and gene fusion, etc.). The disease control rates (DCR), progression-free survival (PFS) and overall survival (OS) of the patients, who received the first line therapy, were retrospectively reviewed to analyze the relationship between signaling pathway as well as its genetic variation and the prognosis of cholangiocarcinoma patients. Results: The median PFS of patients with and without TP53 mutation was 11.0 and 8.3 months, respectively (P=0.332), while OS was 14.3 and 32.9 months, respectively (P=0.041). The median PFS of patients with and without PI3K mutations was 8.3 and 11.0 months, respectively (P=0.285), while OS was 14.3 and 37.0 months, respectively (P=0.020). The median PFS of patients with and without mTOR pathway mutations was 6.3 and 10.3 months, respectively (P=0.020), while OS was 15.6 and 19.6 months, respectively (P=0.892). There was no significant effect of pathway-related gene mutations on patients’survival. Conclusion: The prognosis of cholangiocarcinoma patients with TP53 and PI3K pathway activation had obviously poor prognosis than those without. No significant difference was observed between the patients with and without mTOR pathway activation and IDH mutation.
- Full text:20190213.pdf
